(Q54717571)

3 June 2018

editorial

0 references

title

Metabolomics: integration of a new "omics" with clinical pharmacology. (English)

1 reference

3 June 2018

1 reference

1 reference

L P James

1

1 reference

3 June 2018

language of work or name

English

0 references

publication date

1 November 2013

1 reference

3 June 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

3 June 2018

volume

94

1 reference

3 June 2018

issue

5

1 reference

3 June 2018

page(s)

547-551

1 reference

3 June 2018

https://scigraph.springernature.com/pub.10.1038/clpt.2013.166

exact match

0 references

cites work

High resolution 1H n.m.r. studies of vertebrate blood and plasma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Metabolic phenotyping of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Metabolomics in drug discovery and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

The Application of Metabonomics to Predict Drug-Induced Liver Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Metabolomics: a global biochemical approach to the study of central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Pharmaco-metabonomic phenotyping and personalized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

Acylcarnitine profiles in acetaminophen toxicity in the mouse: comparison to toxicity, metabolism and hepatocyte regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.166

21 January 2018

Identifiers

DOI

10.1038/CLPT.2013.166

1 reference

3 June 2018

Dimensions Publication ID

1053060567

0 references

1 reference

3 June 2018